Courtney's questions to Gilead Sciences Inc (GILD) leadership • Q3 2024
Question
An analyst identified as Courtney asked for details on the competitive pressures facing Yescarta, seeking to dimensionalize the impact from both in-class and out-of-class competitors and whether this necessitates a change in commercial strategy.
Answer
Cindy Perettie, EVP of Kite, explained that in-class competition stems from two new indications in follicular and mantle cell lymphoma and increased competitor manufacturing capacity. Out-of-class pressure comes from bispecifics, with the impact split roughly 50-50. Perettie stated that no strategic pivot is needed, as it's common for physicians to try new therapies, and Gilead remains confident in its plans to expand into community settings and build on its leadership position ahead of the anito-cel launch.